Skip to content
NewsBlazeIN – Lifestyle
Author:
Zymeworks Inc.
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
August 25, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
August 11, 2026
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 6, 2026
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
July 16, 2026
Zymeworks to Acquire Theravance Biopharma, Inc.
June 29, 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
June 15, 2026
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
May 15, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
May 13, 2026
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 8, 2026
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
April 23, 2026
1
2
Next Page
→